Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current HIV/AIDS Reports
Erschienen in: Current HIV/AIDS Reports 4/2015

01.12.2015 | Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

verfasst von: R. Martin-Iguacel, J. M. Llibre, N. Friis-Moller

Erschienen in: Current HIV/AIDS Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

With more effective and widespread antiretroviral treatment, the overall incidence of AIDS- or HIV-related death has decreased dramatically. Consequently, as patients are aging, cardiovascular disease (CVD) has emerged as an important cause of morbidity and mortality in the HIV population. The incidence of CVD overall in HIV is relatively low, but it is approximately 1.5–2-fold higher than that seen in age-matched HIV-uninfected individuals. Multiple factors are believed to explain this excess in risk such as overrepresentation of traditional cardiovascular risk factors (particularly smoking), toxicities associated with cumulative exposure to some antiretroviral agents, together with persistent chronic inflammation, and immune activation associated with HIV infection. Tools are available to calculate an individual’s predicted risk of CVD and should be incorporated in the regular follow-up of HIV-infected patients. Targeted interventions to reduce this risk must be recommended, including life-style changes and medical interventions that might include changes in antiretroviral therapy.
Literatur
1.
Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. JAIDS J Acquir Immune Defic Syndr. 2006;43:27–34.CrossRefPubMed
2.
Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241–8.CrossRefPubMed
3.
Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. Okulicz JF, editor. PLoS ONE. 2013;8:e81355.
4.
Klein D, Hurley LB, Quesenberry CP, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? JAIDS J Acquir Immune Defic Syndr. 2002;30:471–7.CrossRefPubMed
5.
Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, et al. Coronary heart disease in HIV-infected individuals. JAIDS J Acquir Immune Defic Syndr. 2003;33:506–12.CrossRefPubMed
6.
Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479–86.CrossRefPubMed
7.
8.
Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sørensen HT, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44:1625–31.CrossRefPubMed
9.
Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS. 2010;24:1228–30.CrossRefPubMed
10.
Durand M, Sheehy O, Baril J-G, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case–control study using Québec’s public health insurance database. J Acquir Immune Defic Syndr. 2011;57:245–53.CrossRefPubMed
11.•
Freiberg MS, Chang C-CH, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614. This study from the Veterans Aging Cohort Study (VACS) virtual cohort, reported a hazard ratio (HR) for MI of HR 1.48 (95% CI 1.27-1.72) after adjusting for Framingham risk factors, comorbid diseases and substance abuse. Notably, the CV risk persisted in patients achieving HIV RNA levels < than 500 c/ml (HR 1.39, 95% CI, 1.17-1.66).CrossRefPubMed
12.•
Silverberg MJ, Leyden WA, Xu L, Horberg MA, Chao CR, Towner WJ, et al. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014;65:160–6. This study from the Kaiser group reported a RR of AMI of 1.44 (95% CI, 1.27-1.64), after adjusting for tradicional CVD risk factors. Interestingly, the rates of MI were similar in both groups when the analysis was restricted to HIV-infected patients with recent or nadir CD4 cell count ≥ 500 c/ml (RR 0.85, 95% CI 0.55-1.33).CrossRefPubMed
13.••
Klein DB, Leyden WA, Xu L, Chao CR, Horberg MA, Towner WJ, et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis. 2015. This study from the Kaiser group, assessed MI risk in HIV individuals by calendar era form 1996 to 2011 and found that there was no longer an elevated risk for MI among the HIV individuals compared to matched HIV uninfected subjects in the latest period from 2010 to 2011 (adjusted RR 1.0, 95% CI, 1.07-1.4). They report that the CV risk profile for both groups were similar in this period, even more favorable in the HIV positive group.
14.
Paisible A-L, Chang C-CH, So-Armah KA, Butt AA, Leaf DA, Budoff M, et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr. 2015;68:209–16.CrossRefPubMed
15.
Butt AA, Chang C-C, Kuller L, Goetz MB, Leaf D, Rimland D, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171:737–43.PubMedCentralPubMed
16.
Sico JJ, Chang C-CH, So-Armah K, Justice AC, Hylek E, Skanderson M, et al. HIV status and the risk of ischemic stroke among men. Neurology. 2015;84:1933–40.CrossRefPubMed
17.
Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK, et al. Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol. Elsevier Inc; 2012;59:1891–6.
18.
Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;:n/a–n/a.
19.
Abd-Elmoniem KZ, Unsal AB, Eshera S, Matta JR, Muldoon N, McAreavey D, et al. Increased coronary vessel wall thickness in HIV-infected young adults. Clin Infect Dis. 2014;59:1779–86.CrossRefPubMed
20.
Post WS, Budoff M, Kingsley L, Palella FJ, Witt MD, Li X, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014;160:458–67.PubMedCentralCrossRefPubMed
21.
Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24:243–53.PubMedCentralCrossRefPubMed
22.
Freitas P, Carvalho D, Santos AC, Madureira AJ, Martinez E, Pereira J, et al. Carotid intima media thickness is associated with body fat abnormalities in HIV-infected patients. BMC Infect Dis. 2014;14:348.PubMedCentralCrossRefPubMed
23.
Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23:1841–9.PubMedCentralCrossRefPubMed
24.
Chanthong P, Lapphra K, Saihongthong S, Sricharoenchai S, Wittawatmongkol O, Phongsamart W, et al. Echocardiography and carotid intima–media thickness among asymptomatic HIV-infected adolescents in Thailand. AIDS. 2014;28:2071–9.PubMedCentralCrossRefPubMed
25.
Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23:1059–67.PubMedCentralCrossRefPubMed
26.
Pereyra F, Lo J, Triant VA, Wei J, Buzon MJ, Fitch KV, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS. 2012;26:2409–12.PubMedCentralCrossRefPubMed
27.
Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case–control study. Lancet. 2006;368:647–58.CrossRefPubMed
28.
Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d’Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179–93.CrossRefPubMed
29.•
Rasmussen LD, Helleberg M, May MT, Afzal S, Kronborg G, Larsen CS, et al. Myocardial infarction among danish HIV-infected individuals: population-attributable fractions associated with smoking. Clin Infect Dis. 2015. In this study a population-based nationwide HIV cohort (Danish HIV Cohort Study) was compared to a matched background population and found that cigarette smoking in the HIV-population was associated with a higher risk of MI compared to the general population.
30.•
Helleberg M, Afzal S, Kronborg G, Larsen CS, Pedersen G, Pedersen C, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis. 2013;56:727–34. In this study the Danish HIV cohort was compared to a matched background population and found that the loss of life-years associated with smoking was larger than that associated with HIV. Besides, the population-attributable risk of death associated with smoking was doubled in the HIV population compared to the general population.CrossRefPubMed
31.••
Petoumenos K, Worm S, Reiss P, De Wit S, d’Arminio Monforte A, Sabin C, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study*. HIV Med. 2011;12:412–21. Analysis from the D:A:D study found that the risk of CVD in the HIV-population decreased with increasing time since stopping smoking. These results highlight the importance of the effort to motivate smoking cessation in this population.PubMedCentralCrossRefPubMed
32.
Baekken M, Os I, Sandvik L, Oektedalen O. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. J Hypertens. 2008;26:2126–33.CrossRefPubMed
33.
Thiébaut R, El-Sadr WM, Friis-Møller N, Rickenbach M, Reiss P, Monforte AD, et al. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther. 2005;10:811–23.PubMed
34.
Palacios R, Santos J, García A, Castells E, González M, Ruiz J, et al. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients. HIV Med. 2006;7:10–5.CrossRefPubMed
35.
Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS. 2006;20:1019–26.CrossRefPubMed
36.
Seaberg EC, Muñoz A, Lu M, Detels R, Margolick JB, Riddler SA, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19:953–60.CrossRefPubMed
37.
Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, et al. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (D:A:D study). Circulation. 2009;119:805–11.PubMedCentralCrossRefPubMed
38.
Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179–84.CrossRefPubMed
39.
Rasmussen LD, Mathiesen ER, Kronborg G, Pedersen C, Gerstoft J, Obel N. Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. Atashili J, editor. PLoS ONE. 2012;7:e44575.
40.
De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2008;31:1224–9.PubMedCentralCrossRefPubMed
41.
Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV cohort study. Clin Infect Dis. 2007;45:111–9.CrossRefPubMed
42.
Friis-Møller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.CrossRefPubMed
43.•
D:A:D study group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte AD, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–35. This study from the D:A:D study group was one of the first studies to describe the excess risk of CVD in patients treated with ART.CrossRef
44.
Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti‐HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318–30.CrossRefPubMed
45.
Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360:1747–8.CrossRefPubMed
46.
Iloeje UH, Yuan Y, L’italien G, Mauskopf J, Holmberg SD, Moorman AC, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med. 2005;6:37–44.CrossRefPubMed
47.
Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case–control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med. 2010;170:1228–38.CrossRefPubMed
48.
Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. JAIDS J Acquir Immune Defic Syndr. 2009;51:20–8.CrossRefPubMed
49.
Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med. 2010;11:130–6.CrossRefPubMed
50.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–96.CrossRef
51.
SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008;149:289–99.CrossRef
52.
Monforte AD, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, et al. Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events. AIDS. 2013;27:407–15.CrossRefPubMed
53.
D:A:D study group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417–26.CrossRef
54.
Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008;22:F17–24.CrossRef
55.
Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, et al. Simplification of antiretroviral therapy with tenofovir‐emtricitabine or abacavir‐lamivudine: a randomized, 96‐week trial. Clin Infect Dis. 2009;49:1591–601.CrossRefPubMed
56.
Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS. 2011;25:1289–98.PubMedCentralCrossRefPubMed
57.
58.
Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis. 2011;53:84–91.CrossRefPubMed
59.
Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, et al. Abacavir use and cardiovascular disease events. AIDS. 2011;25:1993–2004.CrossRefPubMed
60.
Ding X, Andraca-Carrera E, Cooper C, Miele P, Kornegay C, Soukup M, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 2012;61:441–7.CrossRefPubMed
61.
Sabin C. Abacavir and increased risk of myocardial infarction. Lancet. 2008;372:803. authorreply804–5.CrossRef
62.
Palella FJ, Althoff KN, Moore RD. Abacavir use and risk for myocardial infarction in the NA-ACCORD. Abstract 749 LB. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). Seattle; 2015.
63.
Bozzette SA, Ake CF, Tam HK, Phippard A, Cohen D, Scharfstein DO, et al. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. JAIDS J Acquir Immune Defic Syndr. 2008;47:338–41.CrossRefPubMed
64.
Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard P-M, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23:1679–88.CrossRefPubMed
65.
Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, Negredo E, Gutierrez F, et al. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. HIV Med. 2014;15:330–8.CrossRefPubMed
66.
Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, et al. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015;60:1842–51.CrossRefPubMed
67.
Baril J, Conway B, Giguère P, Ferko N, Hollmann S, Angel JB. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction. HIV Med. 2013;15:301–10.CrossRefPubMed
68.
Elion R, Cohen C, Gathe J, Shalit P, Hawkins T, Liu HC, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 2011;25:1881–6.CrossRefPubMed
69.
Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, DeJesus E, Antunes F, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis. 2013;208:32–9.CrossRefPubMed
70.
Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154:445–56.PubMedCentralCrossRefPubMed
71.
Molina J-M, Clumeck N, Orkin C, Rimsky LT, Vanveggel S, Stevens M, et al. Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials. HIV Med. 2013;15:57–62.CrossRefPubMed
72.
Rockstroh JK, DeJesus E, Lennox JL, Yazdanpanah Y, Saag MS, Wan H, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63:77–85.CrossRefPubMed
73.
Saumoy M, Sánchez-Quesada JL, Martinez E, Llibre J-M, Ribera E, Knobel H, et al. Atherosclerosis. Atherosclerosis. Elsevier Ltd; 2012;225:200–7.
74.
Eron JJ, Young B, Cooper DA, Youle M, DeJesus E, Andrade Villanueva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. The Lancet. Elsevier Ltd; 2010;375:396–407.
75.
Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. ArticlesOnce-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. The Lancet Infectious Diseases. Elsevier Ltd; 2013;13:927–35.
76.
Clumeck N, Molina J-M, Henry K, Gathe J, Rockstroh JK, DeJesus E, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65:e121–4.CrossRefPubMed
77.
Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, DeJesus E, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65:e118–20.CrossRefPubMed
78.
Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204:1191–201.PubMedCentralCrossRefPubMed
79.
Behrens G, Maserati R, Rieger A, Domingo P, Abel F, Wang H, et al. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther. 2012;17:1011–20.CrossRefPubMed
80.
Campo R, DeJesus E, Bredeek UF, Henry K, Khanlou H, Logue K, et al. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis. 2013;56:1637–45.PubMedCentralCrossRefPubMed
81.
Saumoy M, Ordoñez-Llanos J, Martinez E, Barragán P, Ribera E, Bonet R, et al. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. Antivir Ther. 2011;16:459–68.CrossRefPubMed
82.
Martinez E, d’Albuquerque PM, Pérez I, Pich J, Gatell JM. Abacavir/Lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS Res Hum Retrovir. 2012;:120924062217001.
83.
Falcinelli E, Francisci D, Belfiori B, Petito E, Guglielmini G, Malincarne L, et al. In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients. Thromb Haemost. 2013;110:349–57.CrossRefPubMed
84.
Tunjungputri RN, Van Der Ven AJ, Schonsberg A, Mathan TS, Koopmans P, Roest M, et al. Reduced platelet hyperreactivity and platelet-monocyte aggregation in HIV-infected individuals receiving a raltegravir-based regimen. AIDS. 2014;28:2091–6.CrossRefPubMed
85.
Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis. 2013;208:1436–42.PubMedCentralCrossRefPubMed
86.
Silva EF, Charreau I, Gourmel B, Mourah S, Kalidi I, Guillon B, et al. Decreases in inflammatory and coagulation biomarkers levels in HIV-infected patients switching from enfuvirtide to raltegravir: ANRS 138 substudy. J Infect Dis. 2013;208:892–7.CrossRefPubMed
87.
Trøseid M, Manner IW, Pedersen KK, Haissman JM, Kvale D, Nielsen SD. Microbial translocation and cardiometabolic risk factors in HIV infection. AIDS Res Hum Retrovir. 2014;30:514–22.PubMedCentralCrossRefPubMed
88.
Hileman CO, Longenecker CT, Carman TL, McComsey GA. C-reactive protein predicts 96-week carotid intima media thickness progression in HIV-infected adults naive to antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;65:340–4.CrossRefPubMed
89.
Kuller LH, Tracy R, Belloso W, Wit SD, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. Deeks S, editor. Plos Med. 2008;5:e203.
90.
Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis. 2012;206:1558–67.PubMedCentralCrossRefPubMed
91.
McKibben RA, Margolick JB, Grinspoon S, Li X, Palella FJ, Kingsley LA, et al. Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without hiv infection. J Infect Diss. 2014.
92.
Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. Thorne C, editor. PLoS ONE. 2012;7:e44454.
93.
Rasmussen L, Knudsen A, Katzenstein T, Gerstoft J. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1 infected patients: a nested case–control study. HIV Med. In press. 2015;:1–22.
94.
Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978–82.CrossRefPubMed
95.
Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2008;199:79–86.PubMedCentralCrossRefPubMed
96.
Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. JAIDS J Acquir Immune Defic Syndr. 2010;55:615–9.CrossRefPubMed
97.
Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, et al. Low CD4 + T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51:435–47.CrossRefPubMed
98.
Lang S, Mary-Krause M, Simon A, Partisani M, Gilquin J, Cotte L, et al. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis. 2012;55:600–7.CrossRefPubMed
99.
Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, et al. Associations between immune depression and cardiovascular events in HIV infection. AIDS. 2013;27:2735–48.CrossRefPubMed
100.
van Lelyveld SFL, Gras L, Kesselring A, Zhang S, de Wolf F, Wensing AMJ, et al. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort. AIDS. 2012;26:465–74.CrossRefPubMed
101.
Helleberg M, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Obel N, et al. CD4 decline is associated with increased risk of cardiovascular disease, cancer, and death in virally suppressed patients with HIV. Clin Infect Dis. 2013;57:314–21.CrossRefPubMed
102.
The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;:150720091517005.
103.
D’Agostino RB. Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis. 2012;205:S362–7.PubMedCentralCrossRefPubMed
104.
Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17:491–501.CrossRefPubMed
105.
Lundgren J, Gatell JM, Furrer H, Rockstroh J, EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. www.​eacsociety.​org; 2014.
106.
Friis-Møller N, Worm SW. Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools? Clin Infect Dis. 2007;45:1082–4.CrossRefPubMed
107.
Chew KW, Bhattacharya D, McGinnis KA, Horwich TB, Tseng C-H, Currier JS, et al. Coronary heart disease risk by framingham risk score in hepatitis C and HIV/Hepatitis C-coinfected persons. AIDS Res Hum Retrovir. 2015;:150511140329000.
108.
Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2015.
109.
Salinas JL, Rentsch CT, Marconi VC, Tate J. Cumulative HIV care measures highly associated with acute myocardial infarction. Abstract 746. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). Seattle; 2015.
110.
Thompson-Paul A, Lichtenstein KA, Armon C. Cardiovascular disease risk prediction in the HIV Outpatient Study (HOPS). Abstract 747. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). Seattle; 2015.
111.
Lee FJ, Monterio P. Rosuvastatin vs. protease inhibitor switch for hypercholesterolaemia: a randomised trial - The Statin or Switch (SoS) study. Abstract 733. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). Seattle; 2015.
112.
Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. Elsevier; 2014;63:2889–934.
113.
Clement M, Park LP, Navar-Boggan AM. HIV-infected veterans and the NEW ACC/AHA cholesterol guidelines: got statins? Abstract 750. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). Seattle; 2015.
114.
Mosepele M, Regan S, Meigs JB. Application of new ACC/AHA cholesterol guidelines to an HIV clinical care cohort. Abstract 734. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). Seattle; 2015.
115.
Ray KK, Kastelein JJP, Matthijs Boekholdt S, Nicholls SJ, Khaw KT, Ballantyne CM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35:960–8.CrossRefPubMed
116.
Chastain DB, Henderson H, Stover KR. Epidemiology and management of antiretroviral-associated cardiovascular disease. Open AIDS J. 2015;9:23–37.PubMedCentralCrossRefPubMed
117.
Longenecker CT, Firstname. Rosuvastatin arrests progression of carotid Intima-media thickness in treated HIV. Abstract 137. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). Seattle; 2015.
118.
Lo J. Statin therapy reduces coronary noncalcified plaque volume in HIV patients: a randomized controlled trial. Abstract 136. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). Seattle; 2015.
Metadaten
Titel
Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?
verfasst von
R. Martin-Iguacel
J. M. Llibre
N. Friis-Moller
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 4/2015
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-015-0284-6

Weitere Artikel der Ausgabe 4/2015

Current HIV/AIDS Reports 4/2015 Zur Ausgabe

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Cancer in the HIV-Infected Host: Epidemiology and Pathogenesis in the Antiretroviral Era

HIV and Technology (J Simoni and K Horvath, Section Editors)

Cell Phone-Based and Adherence Device Technologies for HIV Care and Treatment in Resource-Limited Settings: Recent Advances

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Tobacco Use, Use Disorders, and Smoking Cessation Interventions in Persons Living With HIV

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review

HIV and Technology (J Simoni and K Horvath, Section Editors)

Use of Technology for HIV Prevention Among Adolescent and Adult Women in the United States

HIV and Technology (J Simoni and K Horvath, Section Editors)

Technology-Delivered Mental Health Interventions for People Living with HIV/AIDS (PLWHA): a Review of Recent Advances

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise